Immunic AG is a young biotech company based in the Munich biotech hub Martinsried that develops pharmaceuticals in the immunology space, in particular for autoimmune diseases or diseases that have an important immunology component in its pathogenesis.
Mission of Immunic AG: Immunic AG is a start-up biotech company focused on the development of immune modulators to block TH
17- and TH
1-mediated immune and autoimmune responses. The final aim is to develop these drug candidates to clinical proof of concept.
Immunic acquires two promising drug development programs with validated targets known to be relevant in various immune and autoimmune diseases IMU-838: New oral treatment option for Crohn’s disease IMU-366: Potent ...Read More
One of the largest Series A biotech venture capital financings in Germany Venture capital consortium led by renowned sector investors Life Sciences Partners (LSP) and LifeCare Partners (LCP) Immunic focuses ...Read More
Immunic will attend BIO-Europe, which will take place November 7-9 in Cologne, Germany. This conference is one of the world's most important meetings for the biotech Industry. This year the ...Read More